Disease · MONDO_0003210
Comparisons in its trials34
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 34
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: deaths from any cause | 188 of 388 | 135 of 385 | 773 | NCT04163900 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: serious adverse events | 175 of 383 | 126 of 378 | 761 | NCT04163900 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: Objective Response Rate (ORR) | 53 of 284 | 34 of 275 | 559 | NCT04163900 | Trial comparisons |
| Gem+Cisplatin+Nab-paclitaxel vs Gemcitabine + Cisplatin: deaths from any cause | 237 of 294 | 115 of 147 | 441 | NCT03768414 | Trial comparisons |
| Gem+Cisplatin+Nab-paclitaxel vs Gemcitabine + Cisplatin: serious adverse events | 27 of 287 | 11 of 134 | 421 | NCT03768414 | Trial comparisons |
| Substudy 1 vs Substudy 2: deaths from any cause | 74 of 103 | 25 of 44 | 147 | NCT03230318 | Trial comparisons |
| Substudy 1 vs Substudy 2: serious adverse events | 37 of 103 | 16 of 44 | 147 | NCT03230318 | Trial comparisons |
| Chemotherapy (Cisplatin-Gemcitabine) vs Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine): deaths from any cause | 28 of 48 | 24 of 41 | 89 | NCT02807181 | Trial comparisons |
| Chemotherapy (Cisplatin-Gemcitabine) vs Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine): serious adverse events | 17 of 48 | 21 of 41 | 89 | NCT02807181 | Trial comparisons |
| High Dose vs Low Dose: deaths from any cause | 1 of 32 | 0 of 28 | 60 | NCT02392637 | Trial comparisons |
| High Dose vs Low Dose: serious adverse events | 5 of 32 | 1 of 28 | 60 | NCT02392637 | Trial comparisons |
Randomization to LC OR ONCOZENE Bead With Gem-Cis or Gem-Carbo vs Randomization to Gem-Cis or Gem-Carbo: Tumor Response (Overall Response = Complete Response + Partial Response + Progressive Disease + Stable Disease) | 24 of 24 | 22 of 22 | 46 | NCT01648023 | Trial comparisons |
| Randomization to LC OR ONCOZENE Bead With Gem-Cis or Gem-Carbo vs Randomization to Gem-Cis or Gem-Carbo: deaths from any cause | 17 of 24 | 16 of 22 | 46 | NCT01648023 | Trial comparisons |
| Randomization to LC OR ONCOZENE Bead With Gem-Cis or Gem-Carbo vs Randomization to Gem-Cis or Gem-Carbo: serious adverse events | 21 of 24 | 19 of 22 | 46 | NCT01648023 | Trial comparisons |
| Arm A (Pevonedistat) vs Arm B (Pevonedistat, Paclitaxel, Carboplatin): deaths from any cause | 17 of 17 | 15 of 17 | 34 | NCT04175912 | Trial comparisons |
| Arm A (Pevonedistat) vs Arm B (Pevonedistat, Paclitaxel, Carboplatin): serious adverse events | 8 of 17 | 12 of 17 | 34 | NCT04175912 | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy | 16 of 17 | 4 of 4 | 21 | NCT04276090 | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Number of Interventions (Phone Calls) to Assure Patients Attend Followup Appointments. | 0 of 17 | 0 of 4 | 21 | NCT04276090 | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: 30-day Postoperative Serious Adverse Events Related to Pump Implantation | 1 of 17 | 0 of 4 | 21 | NCT04276090 | Trial comparisons |
| Colorectal Liver Metastases vs Intrahepatic Cholangiocarcinoma: Percent of Screened Patients That Are Declined Due to High Risk of Failure as Determined by the Psychosocial Assessment Tool. | 0 of 17 | 0 of 4 | 21 | NCT04276090 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003210/comparisons